Table 2 Characteristics of clinical studies.
Author | Year | Country | Study design | Number of treatment group | Number of control group | MSC source | MSCs dose | Route | Endpoints | Duration | MINORS | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Abumoawad et al. | 2020 | USA | Non-randomized controlled trials | 19 (Low dose: 6; Medium dose: 7; High dose: 6) | 18 | AD-MSCs | Low dose: 1.0 × 105 cells/kg; Medium dose: 2.5 × 105 cells/kg; High dose: 5.0 × 105 cells/kg | MSCs were administered into the renal artery of a post-stenotic kidney | eGFR, iothalamate clearance (Both kidneys), systolic blood pressure, urine protein, blood flow, Hypoxia(Cortical R2*, Fractional hypoxia), sGFR (single-kidney glomerular filtration), VEGF-A, VEGF-C, angiopoietin-2, NGAL, IFN-γ, TIMP-2 | 3 months | 16 |
2 | Saad et al. | 2017 | USA | Open-label, non-randomized controlled trials | 14 (Low dose: 7; High dose: 7) | 14 | AD-MSCs | Low dose: 1.0 × 105 cells/kg; High dose: 2.5 × 105 cells/kg | Patients received single intra-arterial infusion of autologous MSCs in the renal artery | Scr, iothalamate clearance GFR, SBP, NGAL, kidney volume, cortical volume, medullary volume, cortical perfusion, medullary perfusion, RBF, Single-kidney GFR, Hypoxia (Cortical R2*, Fractional hypoxia), VEGF-C | 3 months | 16 |
3 | Kim et al. | 2020 | USA | Non-randomized controlled trials | 13 | 6 | AD-MSCs | 5.0 × 105 cells/kg | Patients were treated with a single intra-arterial infusion of MSCs in the renal artery | SBP, DBP, Scr, eGFR, BMI | 3 months | 14 |
